Cargando…

The use of gonadotropin-releasing hormone antagonist post-ovulation trigger in ovarian hyperstimulation syndrome

The purpose of this paper is to assimilate all data pertaining to the use of gonadotropin-releasing hormone (GnRH) antagonists in in vitro fertilization cycles after ovulation trigger to reduce the symptoms of ovarian hyperstimulation syndrome (OHSS). A systematic review of the literature was perfor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chappell, Neil, Gibbons, William E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society for Reproductive Medicine 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5545220/ https://www.ncbi.nlm.nih.gov/pubmed/28795043 http://dx.doi.org/10.5653/cerm.2017.44.2.57

Ejemplares similares

Prevention of Premature Ovulation by Administration of Gonadotropin Releasing Hormone Antagonist the day After Ovulation Triggering in Diminished Ovarian Reserve Patients
por: Sik, Bulat Aytek, et al.
Publicado: (2022)

Gonadotropin releasing hormone antagonist administration for treatment of early type severe ovarian hyperstimulation syndrome: a case series
por: Lee, Dayong, et al.
Publicado: (2017)

Is It Possible to Prevent Ovarian Hyperstimulation Syndrome by Gonadotropin-Releasing Hormone Agonist Triggering and Modified Luteal Support in Patients With Polycystic Ovarian Morphology?
por: Gurbuz, Ali Sami, et al.
Publicado: (2016)

Gonadotropin-releasing hormone agonist ovulation trigger—beyond OHSS prevention
por: Castillo, Juan Carlos, et al.
Publicado: (2020)

Severe ovarian hyperstimulation syndrome and gonadotropin-releasing hormone agonist trigger in patients with hypogonadotropic hypogonadism: A report of two cases
por: Gürbüz, Ali Sami, et al.
Publicado: (2020)

Chorionic gonadotropin: Ovarian hyperstimulation syndrome: case report
Publicado: (2021)

Therapeutic effects of an oral gonadotropin‐releasing hormone receptor antagonist, relugolix, on preventing premature ovulation in mild ovarian stimulation for IVF
por: Nakao, Kazuki, et al.
Publicado: (2021)

Persistent ascites resolving with gonadotropin-releasing-hormone-agonist 18 months after hospitalization for severe ovarian hyperstimulation syndrome
por: Comba, Cihan, et al.
Publicado: (2013)

Association between the luteinizing hormone/chorionic gonadotropin receptor (LHCGR) rs4073366 polymorphism and ovarian hyperstimulation syndrome during controlled ovarian hyperstimulation
por: O’Brien, Travis J, et al.
Publicado: (2013)

Risk of ovarian hyperstimulation syndrome in women with malignancies undergoing treatment with long-acting gonadotropin-releasing hormone agonist after controlled ovarian hyperstimulation for fertility preservation: a systematic review
por: Ingold, Caroline, et al.
Publicado: (2023)

Comparison of Two Regimens of Gonadotropin-releasing Hormone Antagonists in Clomiphene-gonadotropin Induced Controlled Ovulation and Intrauterine Insemination Cycles: Randomized Controlled Study
por: Karthik, Sajja Devendra Siva, et al.
Publicado: (2018)

Hormonal profile in early luteal phase after triggering ovulation with gonadotropin-releasing hormone agonist in high-responder patients
por: Martazanova, Bella, et al.
Publicado: (2022)

The Use of High Dose Letrozole in Ovulation Induction and Controlled Ovarian Hyperstimulation
por: Pritts, Elizabeth A., et al.
Publicado: (2011)

Gonadotropin-releasing hormone agonist for ovulation trigger – OHSS prevention and use of modified luteal phase support for fresh embryo transfer
por: Castillo, Juan Carlos, et al.
Publicado: (2020)

Successful outcome of a pregnancy derived from premature ovulation in a gonadotropin‐releasing hormone antagonist protocol: A case report
por: Inoue, Daichi, et al.
Publicado: (2020)

Comparing the effect of gonadotropin-releasing hormone agonist and human chorionic gonadotropin on final oocytes for ovulation triggering among infertile women undergoing intrauterine insemination: An RCT
por: Taheripanah, Robabeh, et al.
Publicado: (2017)

Investigation of pregnancy outcome and ovarian hyper stimulation syndrome prevention in agonist and antagonist gonadotropin-releasing hormone protocol
por: Rabati, Behnaz Khani, et al.
Publicado: (2012)

Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome – a prospective randomized double-blind clinical trial
por: Engmann, L. L., et al.
Publicado: (2019)

Clinical development of the oral gonadotropin-releasing hormone antagonist elagolix
por: Chwalisz, Kristof
Publicado: (2023)

Dual trigger with gonadotropin-releasing hormone and human chorionic gonadotropin for poor responders
por: Eser, Ahmet, et al.
Publicado: (2018)

Cessation of Gonadotropin-Releasing Hormone Antagonist on Triggering Day: An Alternative Method for Flexible Multiple-Dose Protocol
por: Chang, Hye Jin, et al.
Publicado: (2009)

Ovarian hyperstimulation syndrome
por: Kumar, Pratap, et al.
Publicado: (2011)

Natural autoantibodies to the gonadotropin-releasing hormone receptor in polycystic ovarian syndrome
por: Sattler, Lisa-Marie, et al.
Publicado: (2021)

Diminished Ovarian Reserve Predisposes to Premature Luteinizing Hormone Surges in Gonadotropin-Releasing Hormone Antagonist Cycles in In vitro Fertilization
por: Kochhar, Puneet Kaur, et al.
Publicado: (2020)

Analysis of relative factors and prediction model for optimal ovarian response with gonadotropin-releasing hormone antagonist protocol
por: Jiang, Wenwen, et al.
Publicado: (2022)

Clinical parameters of ovarian hyperstimulation syndrome following different hormonal triggers of oocyte maturation in IVF treatment
por: Abbara, A., et al.
Publicado: (2018)

Fixed Gonadotropin-Releasing Hormone Antagonist Protocol Versus Flexible Progestin-Primed Ovarian Stimulation Protocol in Patients With Asynchronous Follicular Development During Controlled Ovulation Stimulation: A Retrospective Study
por: Dong, Mei, et al.
Publicado: (2021)

Gonadotropin-Releasing Hormone Antagonists—A New Hope in Endometriosis Treatment?
por: Rzewuska, Anna Maria, et al.
Publicado: (2023)

Impact of gonadotropin-releasing hormone antagonist addition on pregnancy rates in gonadotropin-stimulated intrauterine insemination cycles
por: Jain, Shikha, et al.
Publicado: (2016)

A change from gonadotropin releasing hormone antagonist to gonadotropin releasing hormone agonist therapy does not affect the oncological outcomes in hormone sensitive prostate cancer
por: Asakawa, Jumpei, et al.
Publicado: (2018)

Dual trigger with gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves oocyte yield in normal responders on GnRH-antagonist cycles
por: Albeitawi, Soha, et al.
Publicado: (2022)

The relationship between gonadotropin releasing hormone and ovulation inducing factor/nerve growth factor receptors in the hypothalamus of the llama
por: Carrasco, Rodrigo A., et al.
Publicado: (2018)

Fresh versus frozen embryo transfer after gonadotropin-releasing hormone agonist trigger in gonadotropin-releasing hormone antagonist cycles among high responder women: A randomized, multi-center study
por: Aflatoonian, Abbas, et al.
Publicado: (2018)

Long-Acting Luteinizing Hormone-Releasing Hormone Agonist for Ovarian Hyperstimulation Induced by Tamoxifen for Breast Cancer
por: Kojima, Nobue, et al.
Publicado: (2018)

Expression of tissue factor and tissue factor pathway inhibitors during ovulation in rats: a relevance to the ovarian hyperstimulation syndrome
por: Jang, You Jee, et al.
Publicado: (2021)

Nintedanib Treatment After Ovulation is an Effective Therapeutic Strategy for the Alleviation of Ovarian Hyperstimulation Syndrome (OHSS) in a Mouse Model
por: Jiang, Shutian, et al.
Publicado: (2022)

Early onset ovarian hyperstimulation syndrome despite use of segmentation approach and ovarian hyperstimulation syndrome prophylaxis
por: Mahajan, Nalini, et al.
Publicado: (2015)

Reproductive responses of dairy cows with ovarian cysts to simultaneous human chorionic gonadotropin or gonadotropin-releasing hormone and cloprostenol compared to gonadotropin-releasing hormone alone treatment
por: Taktaz, T., et al.
Publicado: (2015)

A randomized controlled trial of gonadotropin-releasing hormone agonist versus gonadotropin-releasing hormone antagonist in Iranian infertile couples: oocyte gene expression
por: Hoseini, Fatemeh Sadat, et al.
Publicado: (2014)

Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Has the Same Effect as Gonadotropin-Releasing Hormone Agonist Injections in Terms of Preparation for Transcervical Resection Myomectomy
por: Ito, Mika, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ul64rn430nd4npkis6mf5vr153